Skip to main content

Table 1 Patient characteristics at the time of histological diagnosis of non-alcoholic fatty acid liver disease (NAFLD)

From: PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

Demographic data  
Numbers of patients 477
Gender, male/female, n 282/195
Age, year* 53 (20–87)
Body mass index, kg/m2* 26.3 (16.6–42.4)
Waist circumference, cm* 91.3 (68.2–132.1)
Smoking, absence/presence, n 385 /92
Previous or current events  
Cardiovascular diseases, absence/presence/unknown, n 444/30/3
Malignancies, except for liver cancer, absence/presence/unknown, n 426/47/4
Liver-related events, absence/presence/unknown, n 432/42/3
 Liver cancer, absence/presence/unknown, n 446/30/1
 Ascites, absence/presence/unknown, n 472/2/3
 Hepatic encephalopathy, absence/presence/unknown, n 474/0/3
 Jaundice, absence/presence/unknown, n 471/3/3
 Esophago-gastric varices, absence/presence/unknown, n 463/11/3
Comorbid diseases  
Type 2 diabetes mellitus, absence/presence, n 321/156
Hypertension, absence/presence, n 256/221
Dyslipidemia, absence/presence, n 125/352
Hyperuricemia, absence/presence, n 420/57
Chronic kidney disease, absence/presence, n 445/32
Histological findings  
Steatosis, 5–33%/ > 33–66%/ > 66%, n 174/175/126
Lobular inflammation  
 No foci/< 2 foci/2–4 foci/> 4 foci per 200 × field, n 28/263/167/17
Ballooning, none/few cells/many cells, n 42/298/135
Fibrosis stage, 0/1/2/3/4, n 55/189/77/121/35
NAFLD activity score, ≤ 2/3/4/ ≥ 5, n 38/197/242
Genetic factors  
PNPLA3 rs738409 (CC/CG/GG/Not determined) 57/137/135/148
TM6SF2 rs58542926 (CC/CT/TT/Not determined) 248/74/7/148
ALDH2 rs671 (GG/GA/AA/Not determined) 158/142/29/148
HSD17B13 rs6834314 (AA/AG/GG/Not determined) 162/132/25/158
Laaboratory dataa  
Serum aspartate aminotransferase (AST), U/L 44 (3–378)
Serum alanine aminotransferase (ALT), U/L 69 (13–783)
Gamma-glutamyl transpeptidase, U/L 71 (11–1,135)
Platelet count, × 103/mm3 212 (40–471)
Albumin 4.1 (2.8–6.9)
Serum ferritin, μg/L 227 (< 10–2.067)
High sensitive C-reactive protein, mg/dL 0.097 (0.004–2.240)
FIB-4 index 1.36 (0.19–14.8)
  1. Data represent number of patients, except those denoted by a, which represent the median (range) values
  2. Cardiovascular diseases included coronary artery disease, heart valve disease, arrhythmia, heart failure, hypertension, orthostatic hypotension, shock, endocarditis, diseases of the aorta and its branches, disorders of the peripheral vascular system, and stroke